Letters to the Editor

Metronomic decitabine with venetoclax offers a patient-centered frontline therapeutic approach for TP53-mutated complex-karyotype myeloid neoplasms

Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
University of Maryland School of Medicine, Department of Neurology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Washington University in St. Louis School of Medicine, St. Louis, MO
Washington University in St. Louis School of Medicine, St. Louis, MO
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD
Haematologica Early view Oct 15, 2026 https://doi.org/10.3324/haematol.2026.301724